BFAR BioPharm Asia$0.19 Tradingchance auf 400-500%
Price: $0.19
Free Level2: http://www.otcmarkets.com/stock/BFAR/quote
Website: http://www.biopharmasiainc.com/
Share structue: Issued and Outstanding 50,000,000
Restricted 29,625,000 (59.25%)
Float 20,375,000 (40.75%)
Chart: http://stockcharts.com/freecharts/gallery.html?bfar
Optionen
| Boardmail an "thekey" |
Wertpapier: BioPharm Asia |
Optionen
| Boardmail an "thekey" |
Wertpapier: BioPharm Asia |
t_s_bfar.gif (verkleinert auf 51%)
1) Market Makers created a run up after they have collected some bottom shares since the last run up to $0.23.
2) Someone is accumulting shares cause he knows there is going to be an announcement of the 10Ks and 10Qs Filings pretty soon.
After he stopped buying VFIN shorted the stock heavily back down to the ground of 6 cents.
3) VFIN is selling shares for an insider or insiders cause they know the real story of the company. After a break of selling shares the Market Makers brought it back up and created a rally to create some more momentum and attention in the stock.
Holding a core position for a lotto seems to be the best on BFAR imo.
Optionen
| Boardmail an "thekey" |
Wertpapier: BioPharm Asia |
Klar ist nur, hier wurde letzte Woche einiges gesammelt. Selbst Freitag gab es nochmal einen kleinen 110k Kauf um dementsprechend den SK auf Vortagesbasis.
die These 3, das VFIN shares verkauft ohne Ende ist meiner Meinung nach Quatsch! hinter VFIN steht wohlgemerkt ein Investor der unter Umständen sein Bestand veräußert. Beachtlich trotzdem, die Blocktrades wurden ja alle aus dem ASK gekauft. (ca. 1,5mio Shares)......
Rein vom Charttechnischen Verlauf und der komischen Blocktrades letzte Woche würde mich ein massiver Ausbruch nicht wundern........diese Woche bleibt spannend, auch wenn ich vermute das wir das Volumen der letzten Woche wohl nicht toppen.
Bis Nachmittag
dann gehts wohl erstmal runter *lol* http://www.sharedeals.de/
Optionen
| Boardmail an "Balu4u" |
Wertpapier: BioPharm Asia |
TONGHUA, CHINA -- (Marketwire) -- 11/19/12 -- Biopharm Asia, Inc. (PINKSHEETS: BFAR) is pleased to announce that Biopharm Asia, Inc. has finished the audit of the previous two fiscal years' financial statements. The Company has prepared a 15c 2-11 and is finalizing to submit it with FINRA no later than end of day, November 19, 2012.
An approval of 15c 2-11 application allows a market maker to "make a market" in the Company's stock, conducting principle buy and sell orders.
Through discussion with the Market Maker it is the Company's understanding that FINRA will conduct a review of the 15c 2-11 and follow up with questions and comments. Typically, FINRA would respond within 14 days of the filling. The Market Maker will work with the Company to respond to the questions and comments. Further questions may be raised by FINRA and the Company will continue to respond until FINRA has no further questions. Once FINRA is satisfied with the submission of the 15c 2-11 and the answers to subsequent questions, the Company would be granted an OTCBB listing.
With these steps to have its shares reinstated on the OTCBB the Company is excited to continue its commitment to increasing transparency, exposure and providing liquidity for its shareholders.
http://www.finanznachrichten.de/...reinstate-listing-on-otcbb-256.htm
Optionen
| Boardmail an "Z3black" |
Wertpapier: BioPharm Asia |
Optionen
| Boardmail an "thekey" |
Wertpapier: BioPharm Asia |
On March 25, 2011, China Northern Pharmacy Holding Group Limited, a wholly-owned subsidiary of BioPharm Asia, Inc. (the “Company”), entered into an agreement to transfer all of the outstanding shares of its subsidiary Tonghua S&T Medical & Pharmacy Company Limited (“PHARMACY”) and its subsidiary Yunnan Silin Pharmaceutical Company Limited (“Silin”) to City Well International Limited for RMB 200 million, or approximately $30.5 million, based upon prevailing exchange rates.
Source : http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7821458
If we can trust all numbers and the Entry into a Material Definitive Agreement as of March 25, 2011, we come up with
Cash and cash equivalents $ 15,407,736
+ cash of Sale of its subsidiary Tonghua S&T Medical & Pharmacy Company Limited (“PHARMACY”) and its subsidiary Yunnan Silin Pharmaceutical Company Limited (“Silin”) of approximately $30.5 M
That´s total approximately $45.9M
Current mkt cap is only $2M
Optionen
| Boardmail an "thekey" |
Wertpapier: BioPharm Asia |